New hope for Hard-to-Treat stomach cancer: drug cocktail trial launches
NCT ID NCT06630130
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase II trial is testing a combination of three drugs—trastuzumab deruxtecan, capecitabine, and rilvegostomig—in people with HER2-positive, locally advanced stomach cancer that cannot be removed by surgery right away. The goal is to see if giving these drugs before and after surgery can shrink the tumor and improve outcomes. The study will enroll 50 adults and track safety, tumor response, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (Enhertu), capecitabine (Xeloda), and rilvegostomig (AZD2936)
What this could lead to
If successful, this could point toward a new combination treatment that shrinks or controls advanced gastric cancer before and after surgery, potentially improving survival.
What could go wrong
This is a small, early-phase (phase II) trial with only 50 participants, so results may not apply to all patients. The drugs can cause serious side effects, and the combination may not work better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact